Xcout Intel
PHILOGEN
Philogen is a Swiss-Italian biotechnology company that focuses on the research, development, and commercialization of targeted therapeutics for the treatment of cancer and other serious conditions. The company utilizes proprietary antibody-based technologies to develop biopharmaceuticals, immunotherapies, and radio-conjugates for oncology and imaging applications.
Subscribe to see PHILOGEN’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PHILOGEN at a glance
PHILOGEN is a biotech company headquartered in Italy. Xcout tracks 19 named people at PHILOGEN, including Henry D. Fahman (Chairman, Chief Executive Officer, President & Acting Chief Financial Officer).
PHILOGEN leadership
- Henry D. FahmanChairman, Chief Executive Officer, President & Acting Chief Financial Officer
- Frank StankunasPresident, Secretary & Director - Cornerstone Biomass Corp
- Horace HorumbaPresident of Eastern Europe
- Venkateswar Rao GopisettiPresident of PHIVITAE Healthcare, Inc. & MD of PHI Vietnam Investment & Development Ltd.
- Dario NeriChief Executive Officer & Chief Scientific Officer Co-founder
- Giovanni NeriHead of Licensing & IP Co-founder
13 more named people on record for PHILOGEN, with roles, board committees and tenure — see the full roster →
PHILOGEN competitors
A few of PHILOGEN's closest competitors — see the full list of competitors and alternatives →
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Theragene Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in Los Angeles, California, focusing on immunotherapy technologies.
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Get PHILOGEN's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on PHILOGEN in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access